Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study.
Snydman
D R
DR
New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA.
Falagas
M E
ME
Avery
R
R
Perlino
C
C
Ruthazer
R
R
Freeman
R
R
Rohrer
R
R
Fairchild
R
R
O'Rourke
E
E
Hibberd
P
P
Werner
B G
BG
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016572:Cyclosporine / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use*; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects; D007136:Immunoglobulins / Q000009:adverse effects / Q000627:therapeutic use*; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D010919:Placebos; D014019:Tissue Donors
D000998:Antiviral Agents; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D010919:Placebos; C045781:cytomegalovirus-specific hyperimmune globulin; D016572:Cyclosporine; D015774:Ganciclovir